רקע כהה למעלה
EverPatch tweezers.png

CorNeat EverPatch 

Permanent tissue-integrating ophthalmic surgical matrix

About Ophthalmic Reconstructive Surgery

Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused unintentionally during a surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible making patching the area with preserved and processed tissue the only treatment option.

Image by Olga Guryanova

CorNeat KPro

רקע כהה למעלה

CorNeat EverPatch Advantages 

icon-222.png

Everlasting 

Inert and non-degradable material

Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response

icon-888.png

Ease of

Handling

Extremely easy to handle and suture

-

Elastic and durable (cannot be torn by the sutures)

icon-444.png

Safe 

Synthetic and therefore cannot carry or transmit disease

Biocompatible

Thin (100 microns), minimizing risk of dellen

icon-777.png

Cost-Effective 

Reduces operating time and eye bank costs 

-

Eliminates complexities related to the transportation and storage of biological materials

-

Readily available, off-the-shelf, device

icon-555.png

Aesthetic 

Translucent when wet

Hardly visible when implanted subconjunctivally

Eye contact9.jpg

CorNeat EverPatch

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and nondegradable tissue substitute for use in ophthalmic surgeries. The CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.  

 

The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the extracellular matrix, stimulating cellular colonization and integration with the surrounding tissue.

רקע כהה למעלה

Indications 

Reinforcing the sclera and aiding the physical reconstruction of the ocular surface

Concealing irritating ophthalmic implants such as glaucoma tube shunts and scleral sutures, used in scleral fixations of IOLs, displacing the need for preserved tissue/collagen

Covering tissue gaps/weaknesses, resulting from either traumatic, disease related or iatrogenic damage

Eye contact5.jpg

First-In-Human (FIH) Implantation

The FIH implantation of the initial CorNeat EverPatch took place in December 2020 as part of a bilateral glaucoma tube shunt implantation. The surgery was conducted by Dr. Ike Ahmed at the Prism Eye Institute in Toronto, Canada.

The fact this patient underwent the same surgery in both eyes at the same time by the same surgeon presents a unique opportunity to compare the CorNeat EverPatch and current state of the art (scleral patch) – both used to conceal the shunt and protect the overlaying conjunctival tissue.

Below on the right, you can see the eye implanted with the scleral patch and on the left, the eye implanted with the CorNeat EverPatch, both photos were taken two months post-implantation.

 

Picture1.png

Besides the clear aesthetic advantages of the CorNeat EverPatch over the scleral (tissue) patch, the device's clinical advantages are very clear. While the conjunctival tissue overlaying the CorNeat EverPatch is healthy and quiet, congestion and inflammation is clearly visible over the scleral patch – an expected reaction to donor tissue.  

28 patients were implanted with the initial configuration of the CorNeat EverPatch with promising results. A pivotal study for evaluating the performance of the final product is currently underway. 


For more information about clinical trials please visit clinicaltrials.gov.

רקע כהה למעלה

Regulatory Path

The CorNeat EverPatch is following a 510K clearance path and is expected to be approved for marketing early in 2023, with the following intended use: implantation to reinforce the sclera and aid the physical reconstruction of the ocular surface. 

The current pivotal study is geared toward obtaining a CE marking early in 2024, for wider indications that include: the concealment of artificial ophthalmic implants, such as glaucoma shunts and scleral sutures used in scleral fixations of IOLs, from the overlying conjunctiva. 

 

The plans above are subject to regulatory approvals and requirements.

 
Product Animation